Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Bevacizumab + Tivantinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bevacizumab||Avastin||VEGF Antibody 10 VEGFR Inhibitor (Pan) 32||Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).|
|Tivantinib||ARQ197|ARQ 197|ARQ-197||MET Inhibitor 55||Tivantinib (ARQ197) is a selective MET inhibitor, which may induce cell death in tumor cells overexpressing MET, although the antimitotic effect may be more responsible for the anti-tumor activity (PMID: 28246274).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT01749384||Phase I||Bevacizumab + Tivantinib||Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery||Completed|